SCHEMBL8937973

SCHEMBL8937973

Cc1cc2c(=O)[nH]ccc2cc1OC1CCN(Cc2cccnc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 1/20 0.51
SCN8A Q9UQD0 3/20 0.43
SCN9A Q15858 1/20 0.43
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
TYK2 P29597 1/20 0.42
JAK3 P52333 1/20 0.42
PRKACA P17612 3/20 0.41
PRKACG P22612 3/20 0.41
PRKACB P22694 3/20 0.41
SCN1A P35498 2/20 0.40
PIK3CA P42336 1/20 0.40
MTOR P42345 1/20 0.40
AURKB Q96GD4 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM3 P20309 1/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937933 0.89 ROCK1 (0.54) ROCK1SCN8ASCN9AJAK2JAK1
SCHEMBL8937945 0.89 ROCK1 (0.56) ROCK1SCN8AJAK1PRKACAPRKACG
SCHEMBL8993394 0.86 ROCK1 (0.53) ROCK1SCN8APRKACAPRKACGPRKACB
SCHEMBL8937943 0.85 ROCK1 (0.56) ROCK1SCN8APRKACAPRKACGPRKACB
SCHEMBL8937993 0.84 ROCK1 (0.52) ROCK1SCN8APRKACAPRKACGPRKACB
SCHEMBL8934875 0.84 ROCK1 (0.54) ROCK1SCN9APRKACAPRKACGPRKACB
SCHEMBL8937994 0.84 ROCK1 (0.55) ROCK1PRKACAPRKACGPRKACBMAOA
SCHEMBL8937944 0.83 ROCK1 (0.52) ROCK1SCN8APRKACAPRKACGPRKACB
SCHEMBL8937925 0.83 ROCK1 (0.54) ROCK1PRKACAPRKACGPRKACBMAOA
SCHEMBL8937839 0.83 ROCK1 (0.52) ROCK1SCN8ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385047-B1 Piperidinyl-substituted isoquinolone derivatives SANOFI SA (FR) 2013-05-29 EP disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2385047-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI (FR) 2011-11-09 EP disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives MYLK2, MYLK, RHOT2 ROCK1 8/4885SCN8A 2875/4885SCN9A 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.